HIMS Stock Jumps Premarket: CEO Targets 100K Monthly Wegovy Push After Novo Nordisk Truce

• The CEO said Hims shipped its first Novo Nordisk medicines nearly two weeks ago.
• As part of the Novo deal, patients gained access to multiple Wegovy injection and pill dose options.
• Dudum’s outlook comes after CFO Yemi Okupe recently disclosed plans to sell shares under a Rule 10b5-1 trading plan.

Shares of Hims & Hers Health Inc. (HIMS) jumped 7% in premarket trading on Wednesday after CEO Andrew Dudum said the telehealth firm is on track to deliver over 100,000 Wegovy prescriptions per month following its truce with Novo Nordisk.

HIMS stock slid over 4% on Tuesday, but gained over 6% in extended trading. 

HIMS Targets 100K Wegovy Monthly Prescriptions

Dudum said on X that the company shipped its first Novo Nordisk medicines nearly two weeks ago as part of a “strategic shift” in its weight-loss business and is already tracking toward a run rate of over 100,000 Wegovy prescriptions each month. “More treatment options mean more customers can find what works best for them,” Dudum said.

The update comes after Novo dropped its patent-infringement lawsuit tied to Hims & Hers’ earlier compounded GLP-1 offerings and instead reached an arrangement allowing the drugmaker to transition patients toward U.S. Food and Drug Administration (FDA) approved treatments.

Under the deal, Hims & Hers said it will discontinue marketing compounded GLP-1 alternatives and instead offer branded Wegovy alongside Ozempic for patients with Type 2 diabetes.

Eligible patients will have access to multiple Wegovy injection doses ranging from 0.25 milligrams to 2.4 milligrams, along with pill-based formulations across several doses. Ozempic injection pens will also be available in doses ranging from 0.25 milligrams to 2 milligrams for diabetes management.

Dudum’s comments reinforce confidence in the company’s outlook after CFO Yemi Okupe recently disclosed plans to sell up to 240,560 shares worth about $4.89 million under a pre-arranged Rule 10b5-1 trading plan, as Hims & Hers ramps its Novo Nordisk-backed GLP-1 rollout. 

HIMS Gets Boost From Novo Deal And Peptides Optimism

The update comes amid rising optimism around Hims as FDA officials are reportedly moving to allow compounding pharmacies to manufacture more than a dozen injectable peptides that were restricted in 2023 over potential safety risks.

Last month, Barclays raised its price target on the stock to $29 from $25 and maintained an ‘Overweight’ rating, saying the Novo Nordisk deal removes a key legal uncertainty and reflects expanding opportunity tied to new product launches. Needham also said that the market may still be “underappreciating” demand potential from cash-pay access to Wegovy pill formulations.

How Do Retail Traders Feel About HIMS?

On Stocktwits, retail sentiment for HIMS slipped to ‘bearish’ over the past week from ‘bullish’ levels a month ago amid ‘extremely low’ message volume.

One user said HIMS is “significantly undervalued with some estimates placing its intrinsic value as much as 66% to 75% higher than current trading levels. New highs in 2026 now possible”

Another user said, “There’s really no bear case here anymore. Literally none.”

Over the past year, HIMS stock has declined nearly 30%.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: Nebius Stock On Hottest Streak In Nearly A Month, Retail Sentiment Climbs Amid Iran Volatility